# Precogify Pharmaceutical China Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precogify-pharmaceutical-china-co

- Industry: Healthcare Specialists
- Headquarters: Beijing, China
- Website: www.zjpkyy.com
- Latest round: Series A (Feb 14, 2022)
- Investors on record: 4

## About

Founded in 2016 and based in Beijing, China, Precogify Pharmaceutical China Co., Ltd., also known as Zhongjing Pukang operates as a tumours screening service provider that offers assessment models for cancer risk. In April 2018, the company closed angel funding from new investor Taiyu Investment. In February 2022, it raised series A funding led by new investor Ourui Hongrun Venture Capital, with participation from other new investors PKU Collaborative Venture and Zhongguancun Qihang Fund.

Using mass spectrometry testing as a platform and relying on self-developed disease mechanism data discovery technology (B-GPS), the company focuses on metabolomic testing research, development and clinical application for early tumours screening and precision treatment. The company's cancer risk assessment model can be used to detect colorectal cancer, gastrointestinal tumours, and other pan-cancer early screening.

The company generates revenue by offering a range of cancer risk assessment models and early tumour screening services.

## Funding rounds

- Series A, Feb 14, 2022 — PKU Collaborative Venture, Ourui Hongrun Venture Capital, Zhongguancun Qihang Fund
- Angel, Apr 4, 2018 — TigerYeah Capital

## Investors

- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Angel
- PKU Collaborative Venture (https://capitalatlas.ai/funds/pku-collaborative-venture) — Series A
- Ourui Hongrun Venture Capital (https://capitalatlas.ai/funds/ourui-hongrun-venture-capital) — Series A
- Zhongguancun Qihang Fund — Series A